vTv Therapeutics (VTVT) Stock: Gaining On Patent News

0
871
vTv Therapeutics VTVT Stock News

vTv Therapeutics Inc (NASDAQ: VTVT) is having a great start to the trading session this morning. However, if you’re looking for press releases or SEC filings, you’re not going to find any. The reason for the gains is a newly issued patent that the company hasn’t yet announced. Today, we’ll talk about:

  • The patent;
  • what we’re seeing from VTVT stock as a result; and
  • what we’ll be watching for ahead.

VTVT Receives A New Patent

As mentioned above, vTv Therapeutics is having a strong day in the market today, but the company hasn’t released any news. So, what’s the deal?

The United States Patent and Trademark Office (USPTO) published a new patent that was granted to the company. The patent, number, 10,172,840 B2 is titled “BACH1 INHIBITORS IN COMBINATION WITH NRF2 ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS THEROF.”

While vTv Therapeutics is both the Applicant and the Assignee on the patent, the inventor listed is Otis Clinton Attucks. The patent provides coverage for pharmaceutical compositions comprising Bach1 Inhibitors and Nrf2 Activators. The patent also provides VTVT with protection with regard to methods of treating diseases such as psoriasis, multiple sclerosis, and COPD comprising administering a Bach1 Inhibitor and a Nrf2 Activator to a subject in need.

What We’re Seeing From The StockĀ 

One of the first lessons that we learn when we start to work in the market is that the news leads to moves. While vTv Therapeutics didn’t release any news of their own yet, the new patent issued by the USPTO is great news for investors. So, it’s not surprising that they are pushing the stock on a run for the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (11:07), VTVT is trading at $2.56 per share after a gain of $0.19 per share or 8.02% so far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the iWatch Markets team will continue to keep a close eye on VTVT. In particular, we’re interested in following the story surrounding the company’s continued work to expand and develop its pipeline. Nonetheless, we’ll continue to follow the news closely and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the iWatch Markets mailing list below!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here